Furthermore, a previously published four-marker model, including LF2 IgG, LF2 IgA, BGLF2 IgG, and EA-D IgA, was tested in all assays, similarly causing a complete separation of data points, indicating that the Duplex assays perform as well as the Singleplex assay in identifying EBV-positive NPC cases. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.